

INFORMATION DISCLOSURE STATEMENT

Applicant	: Goddard, et al.
App. No	: 10/063,595
Filed	: May 3, 2002
For	: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
Examiner	: Sandra L. Wegert
Art Unit	: 1647

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 15 references to be considered by the Examiner. Also enclosed are 15 non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 16, 2007

By: 

AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,595
	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 1 OF 2	Attorney Docket No.	GNE.3230R1C68

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	BERNER, et al., "Clinicopathological association of CD44 mRNA and protein expression expression in primary breast carcinomas" <i>Histopathology</i> (2003) 42:546-554.	
	2	BROOKS, et al., "cDNA array identification of genes regulated in rat renal medulla in response to vasoressin infusion" <i>Am J Physiol</i> (2003) 284:F218-F228.	
	3	Conrads, et al., "A Combined Proteome and Microarray Investigation of Inorganic Phosphate-induced Pre-osteoblast Cells" <i>Mol. Cell Proteomics</i> , 4(9):1284-1296 (2005).	
	4	Czupalla, et al., "Comparative study of proteinand mRNA expression during osteoclastogenesis" <i>Proteomics</i> 5:3868-3875 (2005).	
	5	Ginestier, et al. 2002. "Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers" <i>Am. J. Pathol.</i> , 161:1223-1233.	
	6	Gronborg, et al. "Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach," <i>Mol Cell Proteomics</i> . 2006, Jan:5(1):157-71. Epub 2005 Oct 8. (ABSTRACT ONLY)	
	7	Kawamoto et al., "Expression Profiles of Active Genes in Human and Mouse Livers," <i>Gene</i> , 1996 Sep 26;174(1):151-8.	
	8	Kwong, et al., "Synchronous global assessment of gene and protein expression in colorectal cancer progression" <i>Genomics</i> , 86:142-158 (2005).	
	9	LEDERMAN, et al. 1991. "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4." <i>Molecular Immunology</i> , 28(11):1171-1181.	
	10	LI, et al. 1980. β -Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities. <i>Proc. Natl. Acad. Sci. USA</i> , 77(6)3211-3214.	
	11	ODA, et al., "Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours" <i>Virchows Arch</i> (1997) 430:99-105	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,595
	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Wegert
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C68

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	12	SUGG, et al., "Cytoplasmic staining of <i>erbB-2</i> but not mRNA levels correlates with differentiation in human thyroid neoplasia" <i>Clinical Endocrinology</i> (1998) 49:629-637.	
	13	TOLER, et al., "Loss of communication in ovarian cancer" <i>American Journal of Obstetrics and Gynecology</i> , (2006)194:e27-e31.	
	14	Washburn, et al., "Protein pathway and complex clustering of correlated mRNA and protein expression analyses in <i>Saccharomyces cerevisiae</i> " <i>Proc. Natl. Acad. Sci.</i> 100(6): 3107-3112. (2003)	
	15	WILDSMITH, et al. "Gene Expression Analysis Using Microarrays" <i>Molecular Biology in Cellular Pathology</i> Ed. John Crocker and Paul G. Murray, pages 269-286.	

3311581:011607/JJH

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.